EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Using Machine Learning to Determine a Suitable Patient Population for Anakinra for the Treatment of COVID ‐19 Under the Emergency Use Authorization

Qi Liu iD, Raj Nair iD, Ruihao Huang iD, Hao Zhu iD, Austin Anderson iD, Ozlem Belen iD, Van Tran iD, Rebecca Chiu iD, Karen Higgins iD, Jianmeng Chen, Lei He, Suresh Doddapaneni iD und 3 weitere

Clinical Pharmacology & Therapeutics · 2024

DOI: 10.1002/cpt.3191 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2024. Verfasst von Qi Liu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver S…. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A randomized, double‐blind, placebo‐controlled study (SAVEMORE trial) provided data to support an Emergency Use Authorization (EUA) of anakinra in hospitalized adults with positive results of direct severe acute respiratory syndrome‐coronavirus 2 viral testing with pneumonia requiring supplemental oxygen (low‐ or high‐flow oxygen) who are at risk of progressing to severe respiratory failure and likely to have an elevated plasma soluble urokinase plasminogen activator receptor (suPAR). Currently, the suPAR assay is not commercially available in the United States. An alternative method was needed to identify patients that best reflect the population in the clinical trial selected based on suPAR level ≥ 6 ng/mL at baseline. A machine learning approach based on data from the SAVEMORE trial was used to develop a scoring rule to identify patients who are likely to have a suPAR level ≥ 6 ng/mL at baseline. External validation of the scoring rule was conducted with data from a different trial (SAVE). This clinical scoring rule with high positive predictive value, high specificity, reasonable sensitivity, and biological relevance is expected to identify patients who are likely to have an elevated suPAR level ≥ 6 ng/mL at baseline. As such, it is included in the EUA to identify patients that fall within the authorized population for whom the known and potential benefits outweigh the known and potential risks of anakinra.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19AdultHumansBiomarkersInterleukin 1 Receptor Antagonist ProteinOxygenPrognosisReceptors, Urokinase Plasminogen ActivatorSARS-CoV-2Randomized Controlled Trials as Topic

Substanzen

BiomarkersInterleukin 1 Receptor Antagonist ProteinOxygenReceptors, Urokinase Plasminogen Activator

Autor:innen und Institutionen

  • Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
  • Office of New Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
  • Office of Biostatistics, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.

ORCID-Profile: Qi Liu, Raj Nair, Ruihao Huang, Hao Zhu, Austin Anderson, Ozlem Belen, Van Tran, Rebecca Chiu, Karen Higgins, Suresh Doddapaneni, Shiew-Mei Huang, Nikolay P Nikolov

Zitieren

APA

Liu, Q., Nair, R., Huang, R., Zhu, H., Anderson, A., Belen, O., Tran, V., Chiu, R., Higgins, K., Chen, J., He, L., Doddapaneni, S., Huang, S. M., Nikolov, N. P., & Zineh, I. (2024). Using Machine Learning to Determine a Suitable Patient Population for Anakinra for the Treatment of COVID ‐19 Under the Emergency Use Authorization. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3191

Vancouver

Liu Q, Nair R, Huang R, Zhu H, Anderson A, Belen O, et al. Using Machine Learning to Determine a Suitable Patient Population for Anakinra for the Treatment of COVID ‐19 Under the Emergency Use Authorization. Clinical Pharmacology & Therapeutics. 2024. doi:10.1002/cpt.3191

BibTeX
@article{Liu2024,
  author = {Liu, Qi and Nair, Raj and Huang, Ruihao and Zhu, Hao and Anderson, Austin and Belen, Ozlem and Tran, Van and Chiu, Rebecca and Higgins, Karen and Chen, Jianmeng and He, Lei and Doddapaneni, Suresh and Huang, Shiew-Mei and Nikolov, Nikolay P and Zineh, Issam},
  title = {Using Machine Learning to Determine a Suitable Patient Population for Anakinra for the Treatment of COVID ‐19 Under the Emergency Use Authorization},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1002/cpt.3191}
}
Kostenlos starten →